CaptureSelectÂ® technology enables new opportunities in the biotherapeutic purification field. BAC has developed a unique affinity ligand discovery program, which has proven itself for a wide variety of target biotherapeutic compounds, ranging from antibodies and antibody fragments, recombinant and plasma proteins to viral particles. CaptureSelect ligands (single domain [VHH] antibody fragments) can be developed for almost any purification challenge, and offer numerous advantages, some of which are listed below.
Click here to download the brochure to find out more about this technology!
BAC BV provides affinity purification products and services for the biopharmaceutical market. Our CaptureSelect products are used for drug discovery upto manufacturing of biopharmaceuticals and are based on a proprietary platform technology, integrating affinity ligand discovery, manufacturing and immobilization of single domain antibodies derived from Camelids. Visit www.bacbv.com to find out more.
BAC will be exhibiting at BioPharma Asia Convention 2012. Pre-register to visit the exhibition today.